PD-L1 Protein (His tag)

Catalog No. ABIN7194779

Recombinant PD-L1 protein expressed in HEK-293 Cells.

Quick Overview for PD-L1 Protein (His tag) (ABIN7194779)

Target: PD-L1 (CD274 (PD-L1))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: HEK-293 Cells

Purity: > 98 % as determined by SDS-PAGE

Product Details

Purification tag / Conjugate: This PD-L1 protein is labelled with His tag.

Purpose: Recombinant Mouse PD-L1/B7-H1/CD274 Protein (His Tag) (Active)

Sequence: Met 1-Thr 238

Characteristics: A DNA sequence encoding the mouse CD274 (NP_068693.1) extracellular domain (Met 1-Thr 238) was fused with a polyhistidine tag at the C-terminus.

Endotoxin Level: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Measured by its binding ability in a functional ELISA. Immobilized recombinant mouse PD1-L1 at 1 μg/ml (100 μl/well) can bind mouse PD1 with a linear range of 6.25-400 ng/ml.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Target Details

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: PD-L1/B7-H1/CD274

Background:

Background: Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Immune CheckpointImmune Checkpoint Blockade: Blocking Antibodies   Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking AntibodiesImmune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies   Immune Checkpoint Detection: IHC Antibodies   Immune Checkpoint Detection: ICC Antibodies   Immune Checkpoint Detection: FCM Antibodies   Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint Proteins   PD-L1 / B7-H1 / CD274 Immune Checkpoint ProteinsImmune Checkpoint Targets   Co-inhibitory Immune Checkpoint Targets Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Synonym: A530045L16Rik Protein, Mouse;B7h1 Protein, Mouse;Pdcd1l1 Protein, Mouse;Pdcd1lg1 Protein, Mouse;Pdl1 Protein, Mouse

Molecular Weight: 26.3 kDa

NCBI Accession: NP_068693

Pathways: Cancer Immune Checkpoints